PI3K/Akt-mediated regulation of p53 in cancer.

Mutations activating the PI3K (phosphoinositide 3-kinase)/Akt signalling pathway and inactivating the TP53 tumour-suppressor gene are common mechanisms that cancer cells require to proliferate and escape pre-programmed cell death. In a well-described mechanism, Akt mediates negative control of p53 levels through enhancing MDM2 (murine double minute 2)-mediated targeting of p53 for degradation. Accumulating evidence is beginning to suggest that, in certain circumstances, PTEN (phosphatase and tensin homologue deleted on chromosome 10)/PI3K/Akt also promotes p53 translation and protein stability, suggesting that additional mechanisms may be involved in the Akt-mediated regulation of p53 in tumours. In the present article, we discuss these aspects in the light of clinical PI3K/Akt inhibitors, where information regarding the effect on p53 activity will be a crucial factor that will undoubtedly influence therapeutic efficacy.

[1]  D. Wong,et al.  Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative , 2007, Clinical Cancer Research.

[2]  Karen H. Vousden,et al.  p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.

[3]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[4]  G. Evan,et al.  The pathological response to DNA damage does not contribute to p53-mediated tumour suppression , 2006, Nature.

[5]  T. Iwakuma,et al.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.

[6]  John P A Ioannidis,et al.  Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. , 2011, Journal of the National Cancer Institute.

[7]  P. Klatt,et al.  Oncogenic activity of Cdc6 through repression of the INK4/ARF locus , 2006, Nature.

[8]  I. Bièche,et al.  Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab , 2013, British Journal of Cancer.

[9]  D. Woods,et al.  Phosphorylation of HDM2 by Akt , 2002, Oncogene.

[10]  C. Korgaonkar,et al.  Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function , 2005, Molecular and Cellular Biology.

[11]  Jun Qin,et al.  Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses , 2010, Nature.

[12]  Michael Baumann,et al.  Stimulated PI3K-AKT Signaling Mediated through Ligand or Radiation-Induced EGFR Depends Indirectly, but not Directly, on Constitutive K-Ras Activity , 2007, Molecular Cancer Research.

[13]  Moshe Oren,et al.  Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis , 2002, Oncogene.

[14]  Sean E. Egan,et al.  Elevated PI3K signaling drives multiple Breast Cancer subtypes , 2011, Oncotarget.

[15]  Michael Berger,et al.  Apoptosis - the p53 network , 2003, Journal of Cell Science.

[16]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[17]  Z. Zong,et al.  CCL19-induced chemokine receptor 7 activates the phosphoinositide-3 kinase-mediated invasive pathway through Cdc42 in metastatic squamous cell carcinoma of the head and neck. , 2011, Oncology reports.

[18]  P. Pandolfi,et al.  Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner , 2013, Cell cycle.

[19]  D. Spandidos,et al.  Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). , 2011, International journal of oncology.

[20]  C. Galbán,et al.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.

[21]  M. Nagai,et al.  PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients , 2012, Clinics.

[22]  Mei-Ling Kuo,et al.  N-terminal polyubiquitination and degradation of the Arf tumor suppressor. , 2004, Genes & development.

[23]  J. Tabernero,et al.  Development of PI3K inhibitors: lessons learned from early clinical trials , 2013, Nature Reviews Clinical Oncology.

[24]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[25]  Naimei Tang,et al.  Akt, FoxO and regulation of apoptosis. , 2011, Biochimica et biophysica acta.

[26]  P. Abbe,et al.  SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival , 2011, Oncogene.

[27]  O. Renner,et al.  Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models , 2010, PloS one.

[28]  C. Coffill,et al.  The role of mutant p53 in human cancer , 2011, The Journal of pathology.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[30]  P. Pandolfi,et al.  Role of the proto-oncogene Pokemon in cellular transformation and ARF repression , 2005, Nature.

[31]  J. Prat,et al.  Concomitant PI3K–AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis , 2009, Modern Pathology.

[32]  C. Ching,et al.  Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway , 2010, Laboratory Investigation.

[33]  David Hawke,et al.  Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. , 2003, Molecular cell.

[34]  A. El‐Naggar,et al.  Multiple stress signals activate mutant p53 in vivo. , 2011, Cancer research.

[35]  B. Gusterson,et al.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.

[36]  Zhaohui Feng,et al.  p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. , 2010, Cold Spring Harbor perspectives in biology.

[37]  C. Sherr.  Divorcing ARF and p53: an unsettled case , 2006, Nature Reviews Cancer.

[38]  Tjalling Bosse,et al.  Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation. , 2012, Gynecologic oncology.

[39]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[40]  J. Norman,et al.  Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.

[41]  C. D. Edwards,et al.  A novel p16INK4A transcript. , 1995, Cancer research.

[42]  Y. Drouet,et al.  Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes , 2012, Breast Cancer Research and Treatment.

[43]  S. Lowe,et al.  The p53–Bcl-2 connection , 2006, Cell Death and Differentiation.

[44]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[45]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[46]  C. Prives,et al.  p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.

[47]  N. Sharpless,et al.  INK4a/ARF: a multifunctional tumor suppressor locus. , 2005, Mutation research.

[48]  Hong-guang Zhu,et al.  Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy , 2004, Cell Research.

[49]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  C. Feschotte,et al.  Endogenous viruses: insights into viral evolution and impact on host biology , 2012, Nature Reviews Genetics.

[51]  U. Moll,et al.  Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis , 2013, Cell Death and Differentiation.

[52]  A. Açıkalın,et al.  PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. , 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[53]  R. Gjerset.  DNA damage, p14ARF, Nucleophosmin (NPM/B23), and cancer , 2006, Journal of Molecular Histology.

[54]  Toshiyuki Obata,et al.  Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53* , 2002, The Journal of Biological Chemistry.

[55]  G. Wahl,et al.  MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.

[56]  Hong Wu,et al.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  D. Schiff,et al.  PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. , 2008, Cancer research.

[58]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[59]  K. Kinzler,et al.  Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.

[60]  R. Pearson,et al.  AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy , 2011, Oncogene.

[61]  W. Gerald,et al.  PIK3CA Mutation Associates with Improved Outcome in Breast Cancer , 2009, Clinical Cancer Research.

[62]  M. Duffy,et al.  Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[64]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  You-ji Feng,et al.  Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway , 2009, Molecular Cancer.

[66]  R. Berger,et al.  A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. , 1995, Oncogene.

[67]  A. Efeyan,et al.  Tumour biology: Policing of oncogene activity by p53 , 2006, Nature.

[68]  H. Ke,et al.  Essential Role of the B23/NPM Core Domain in Regulating ARF Binding and B23 Stability* , 2006, Journal of Biological Chemistry.

[69]  Shantanu Banerji,et al.  Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers , 2013, Clinical Cancer Research.

[70]  Barbara Benassi,et al.  Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation. , 2010, Cancer cell.

[71]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[72]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[73]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[74]  Han You,et al.  Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. , 2006, Genes & development.

[75]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[76]  H. Baba,et al.  PIK3CA Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma , 2013, Clinical Cancer Research.

[77]  M. Oshimura,et al.  PI3K-Akt pathway: Its functions and alterations in human cancer , 2004, Apoptosis.

[78]  N. Hay,et al.  Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. , 2008, Cancer cell.

[79]  Paul Timpson,et al.  Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[80]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[81]  Lao H. Saal,et al.  Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells , 2013, Cancer biology & therapy.

[82]  William R. Jeck,et al.  Expression of Linear and Novel Circular Forms of an INK4/ARF-Associated Non-Coding RNA Correlates with Atherosclerosis Risk , 2010, PLoS genetics.

[83]  G. Sauter,et al.  PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer , 2013, Histopathology.